<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2024//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_240101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Curated"><PMID Version="1">35658531</PMID><DateCompleted><Year>2022</Year><Month>07</Month><Day>25</Day></DateCompleted><DateRevised><Year>2024</Year><Month>08</Month><Day>31</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1098-5514</ISSN><JournalIssue CitedMedium="Internet"><Volume>96</Volume><Issue>13</Issue><PubDate><Year>2022</Year><Month>Jul</Month><Day>13</Day></PubDate></JournalIssue><Title>Journal of virology</Title><ISOAbbreviation>J Virol</ISOAbbreviation></Journal><ArticleTitle>Immunoglobin G Sero-Dynamics Aided Host Specific Linear Epitope Identification and Differentiation of Infected from Vaccinated Hosts.</ArticleTitle><Pagination><StartPage>e0014322</StartPage><MedlinePgn>e0014322</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">e00143-22</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1128/jvi.00143-22</ELocationID><Abstract><AbstractText>Differentiation of infected from vaccinated hosts (DIVH) is a critical step in virus eradication programs. DIVH-compatible vaccines, however, take years to develop, and are therefore unavailable for fighting the sudden outbreaks that typically drive pandemics. Here, we establish a protocol for the swift and efficient development of DIVH assays, and show that this approach is compatible with any type of vaccines. Using porcine circovirus 2 (PCV2) as the experimental model, the first step is to use Immunoglobin G (IgG) sero-dynamics (IsD) curves to aid epitope discovery (IsDAED): PCV2 Cap peptides were categorized into three types: null interaction, nonspecific interaction (NSI), and specific interaction (SI). We subsequently compared IsDAED approach and traditional approach, and demonstrated identifying SI peptides and excluding NSI peptides supports efficient diagnostic kit development, specifically using a protein-peptide hybrid microarray (PPHM). IsDAED directed the design of a DIVH protocol for three types of PCV2 vaccines (while using a single PPHM). Finally, the DIVH protocol successfully differentiated infected pigs from vaccinated pigs at five farms. This IsDAED approach is almost certainly extendable to other viruses and host species. <b>IMPORTANCE</b> Sudden outbreaks of pandemics caused by virus, such as SARS-CoV-2, has been determined as a public health emergency of international concern. However, the development of a DIVH-compatible vaccine is time-consuming and full of uncertainty, which is unsuitable for an emergent situation like the ongoing COVID-19 pandemic. Along with the development and public health implementation of new vaccines to prevent human diseases, e.g., human papillomavirus vaccines for cervical cancer; enterovirus 71 vaccines for hand, foot, and mouth disease; and most recently SARS-CoV-2, there is an increasing demand for DIVH. Here, we use the IsDAED approach to confirm SI peptides and to exclude NSI peptides, finally to direct the design of a DIVH protocol. It is plausible that our IsDAED approach is applicable for other infectious disease.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y" EqualContrib="Y"><LastName>Chen</LastName><ForeName>Xiaochun</ForeName><Initials>X</Initials><AffiliationInfo><Affiliation>China Institute of Veterinary Drug Control, Beijing, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y" EqualContrib="Y"><LastName>Li</LastName><ForeName>Jingzhi</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Division of Nanobiomedicine, Suzhou Institute of Nano-Tech and Nano-Bionics, Chinese Academy of Sciences, Suzhou, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Yang</LastName><ForeName>Lan</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Division of Nanobiomedicine, Suzhou Institute of Nano-Tech and Nano-Bionics, Chinese Academy of Sciences, Suzhou, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zhou</LastName><ForeName>Yuxi</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Division of Nanobiomedicine, Suzhou Institute of Nano-Tech and Nano-Bionics, Chinese Academy of Sciences, Suzhou, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Li</LastName><ForeName>Mengyu</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Division of Nanobiomedicine, Suzhou Institute of Nano-Tech and Nano-Bionics, Chinese Academy of Sciences, Suzhou, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Xu</LastName><ForeName>Wenwen</ForeName><Initials>W</Initials><AffiliationInfo><Affiliation>Division of Nanobiomedicine, Suzhou Institute of Nano-Tech and Nano-Bionics, Chinese Academy of Sciences, Suzhou, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Qin</LastName><ForeName>Yixian</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>China Institute of Veterinary Drug Control, Beijing, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Su</LastName><ForeName>Jia</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>China Institute of Veterinary Drug Control, Beijing, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zhao</LastName><ForeName>Wei</ForeName><Initials>W</Initials><AffiliationInfo><Affiliation>China Institute of Veterinary Drug Control, Beijing, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Gu</LastName><ForeName>Chaoyi</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Suzhou Qiangdong Biotechnology Co. Ltd., Suzhou, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sheng</LastName><ForeName>Shuixing</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Suzhou Animal Husbandry and Veterinary Station, Suzhou, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Pan</LastName><ForeName>Yongfei</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Guangdong Wen's Group Academy, Yunfu, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Xue</LastName><ForeName>Qinghong</ForeName><Initials>Q</Initials><AffiliationInfo><Affiliation>China Institute of Veterinary Drug Control, Beijing, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ma</LastName><ForeName>Hongwei</ForeName><Initials>H</Initials><Identifier Source="ORCID">0000-0003-4214-7142</Identifier><AffiliationInfo><Affiliation>Division of Nanobiomedicine, Suzhou Institute of Nano-Tech and Nano-Bionics, Chinese Academy of Sciences, Suzhou, China.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2022</Year><Month>06</Month><Day>06</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>J Virol</MedlineTA><NlmUniqueID>0113724</NlmUniqueID><ISSNLinking>0022-538X</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000914">Antibodies, Viral</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000939">Epitopes</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D007074">Immunoglobulin G</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D010455">Peptides</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D014765">Viral Vaccines</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000914" MajorTopicYN="Y">Antibodies, Viral</DescriptorName><QualifierName UI="Q000097" MajorTopicYN="N">blood</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000086382" MajorTopicYN="N">COVID-19</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D018173" MajorTopicYN="Y">Circoviridae Infections</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D017925" MajorTopicYN="N">Circovirus</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D004195" MajorTopicYN="N">Disease Models, Animal</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000939" MajorTopicYN="Y">Epitopes</DescriptorName><QualifierName UI="Q000032" MajorTopicYN="N">analysis</QualifierName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007074" MajorTopicYN="Y">Immunoglobulin G</DescriptorName><QualifierName UI="Q000097" MajorTopicYN="N">blood</QualifierName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D010455" MajorTopicYN="N">Peptides</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000086402" MajorTopicYN="N">SARS-CoV-2</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D013552" MajorTopicYN="N">Swine</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D013553" MajorTopicYN="N">Swine Diseases</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D014765" MajorTopicYN="Y">Viral Vaccines</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Immunoglobin G sero-dynamics curve</Keyword><Keyword MajorTopicYN="N">diagnosis</Keyword><Keyword MajorTopicYN="N">differentiation of infected from vaccinated hosts</Keyword><Keyword MajorTopicYN="N">linear epitope identification</Keyword><Keyword MajorTopicYN="N">porcine circovirus 2</Keyword></KeywordList><CoiStatement>The authors declare no conflict of interest.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2022</Year><Month>6</Month><Day>7</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2022</Year><Month>7</Month><Day>26</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2022</Year><Month>6</Month><Day>6</Day><Hour>9</Hour><Minute>31</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2022</Year><Month>12</Month><Day>6</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">35658531</ArticleId><ArticleId IdType="pmc">PMC9278109</ArticleId><ArticleId IdType="doi">10.1128/jvi.00143-22</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Gomez-Sebastian S, Perez-Filgueira DM, Gomez-Casado E, Nunez MC, Sanchez-Ramos I, Tabares E, Escribano JM. 2008. DIVA diagnostic of Aujeszky&#x2019;s disease using an insect-derived virus glycoprotein E. J Virol Methods 153:29&#x2013;35. 10.1016/j.jviromet.2008.06.017.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jviromet.2008.06.017</ArticleId><ArticleId IdType="pubmed">18638504</ArticleId></ArticleIdList></Reference><Reference><Citation>Meeusen EN, Walker J, Peters A, Pastoret PP, Jungersen G. 2007. Current status of veterinary vaccines. Clin Microbiol Rev 20:489&#x2013;510. 10.1128/CMR.00005-07.</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/CMR.00005-07</ArticleId><ArticleId IdType="pmc">PMC1932753</ArticleId><ArticleId IdType="pubmed">17630337</ArticleId></ArticleIdList></Reference><Reference><Citation>Wilder-Smith A, Mulholland K. 2021. Effectiveness of an Inactivated SARS-CoV-2 Vaccine. N Engl J Med 385:946&#x2013;948. 10.1056/NEJMe2111165.</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMe2111165</ArticleId><ArticleId IdType="pmc">PMC8427532</ArticleId><ArticleId IdType="pubmed">34469651</ArticleId></ArticleIdList></Reference><Reference><Citation>The General Office of National Health Commission Office, National TCM Administration. 2021. Diagnosis and Treatment Protocol for COVID-19 Patients (Tentative 8th Edition). Infect Dis Immun 1:8&#x2013;16. 10.1097/01.ID9.0000733564.21786.b0.</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/01.ID9.0000733564.21786.b0</ArticleId><ArticleId IdType="pmc">PMC8057316</ArticleId><ArticleId IdType="pubmed">38630124</ArticleId></ArticleIdList></Reference><Reference><Citation>Xue Q, Xu H, Liu H, Pan J, Yang J, Sun M, Chen Y, Xu W, Cai X, Ma H. 2020. Epitope-containing short peptides capture distinct IgG serodynamics that enable differentiating infected from vaccinated animals for live-attenuated vaccines. J Virol 94. 10.1128/JVI.01573-19.</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/JVI.01573-19</ArticleId><ArticleId IdType="pmc">PMC7158722</ArticleId><ArticleId IdType="pubmed">31896600</ArticleId></ArticleIdList></Reference><Reference><Citation>Rockberg J, Nilvebrant J. 2018. Epitope mapping protocols. Methods in Molecular Biology (Springer protocols) 1785. 10.1007/978-1-4939-7841-0.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/978-1-4939-7841-0</ArticleId><ArticleId IdType="pubmed">29714008</ArticleId></ArticleIdList></Reference><Reference><Citation>Geysen HM, Meloen RH, Barteling SJ. 1984. Use of peptide synthesis to probe viral antigens for epitopes to a resolution of a single amino acid. Proc Natl Acad Sci USA 81:3998&#x2013;4002. 10.1073/pnas.81.13.3998.</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.81.13.3998</ArticleId><ArticleId IdType="pmc">PMC345355</ArticleId><ArticleId IdType="pubmed">6204335</ArticleId></ArticleIdList></Reference><Reference><Citation>Hasan NH, Ebrahimie E, Ignjatovic J, Tarigan S, Peaston A, Hemmatzadeh F. 2016. Epitope mapping of avian influenza M2e protein: different species recognise various epitopes. PLoS One 11:e0156418. 10.1371/journal.pone.0156418.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0156418</ArticleId><ArticleId IdType="pmc">PMC4928777</ArticleId><ArticleId IdType="pubmed">27362795</ArticleId></ArticleIdList></Reference><Reference><Citation>Jacek E, Tang KS, Komorowski L, Ajamian M, Probst C, Stevenson B, Wormser GP, Marques AR, Alaedini A. 2016. Epitope-specific evolution of human b cell responses to borrelia burgdorferi VlsE protein from early to late stages of Lyme disease. J Immunol 196:1036&#x2013;1043. 10.4049/jimmunol.1501861.</Citation><ArticleIdList><ArticleId IdType="doi">10.4049/jimmunol.1501861</ArticleId><ArticleId IdType="pmc">PMC4722499</ArticleId><ArticleId IdType="pubmed">26718339</ArticleId></ArticleIdList></Reference><Reference><Citation>Lippi G, Aloe R, Meschi T, Borghi L, Cervellin G. 2013. Interference from heterophilic antibodies in troponin testing. Case report and systematic review of the literature. Clin Chim Acta 426:79&#x2013;84. 10.1016/j.cca.2013.09.004.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cca.2013.09.004</ArticleId><ArticleId IdType="pubmed">24041812</ArticleId></ArticleIdList></Reference><Reference><Citation>Pan J, Yang L, Wu W, Li J, Cheng H, Li Y, Xu W, Xue Q, Zhou Y, Peng D, Qiu J, Ma H. 2022. Previously unrecognized nonreproducible antibody-probe interactions. Anal Chem 10.1021/acs.analchem.1c03264.</Citation><ArticleIdList><ArticleId IdType="doi">10.1021/acs.analchem.1c03264</ArticleId><ArticleId IdType="pubmed">35044162</ArticleId></ArticleIdList></Reference><Reference><Citation>Pulendran B, Ahmed R. 2011. Immunological mechanisms of vaccination. Nat Immunol 12:509&#x2013;517. 10.1038/ni.2039.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/ni.2039</ArticleId><ArticleId IdType="pmc">PMC3253344</ArticleId><ArticleId IdType="pubmed">21739679</ArticleId></ArticleIdList></Reference><Reference><Citation>Khayat R, Brunn N, Speir JA, Hardham JM, Ankenbauer RG, Schneemann A, Johnson JE. 2011. The 2.3-angstrom structure of porcine circovirus 2. J Virol 85:7856&#x2013;7862. 10.1128/JVI.00737-11.</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/JVI.00737-11</ArticleId><ArticleId IdType="pmc">PMC3147897</ArticleId><ArticleId IdType="pubmed">21632760</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhai SL, Chen SN, Xu ZH, Tang MH, Wang FG, Li XJ, Sun BB, Deng SF, Hu J, Lv DH, Wen XH, Yuan J, Luo ML, Wei WK. 2014. Porcine circovirus type 2 in China: an update on and insights to its prevalence and control. Virol J 11:88. 10.1186/1743-422X-11-88.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/1743-422X-11-88</ArticleId><ArticleId IdType="pmc">PMC4031328</ArticleId><ArticleId IdType="pubmed">24885983</ArticleId></ArticleIdList></Reference><Reference><Citation>Jeong J, Park C, Kim S, Park SJ, Kang I, Park KH, Chae C. 2018. Evaluation of the efficacy of a novel porcine circovirus type 2 synthetic peptide vaccine. Can J Vet Res 82:146&#x2013;153.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5914084</ArticleId><ArticleId IdType="pubmed">29755195</ArticleId></ArticleIdList></Reference><Reference><Citation>Mahe D, Blanchard P, Truong C, Arnauld C, Le Cann P, Cariolet R, Madec F, Albina E, Jestin A. 2000. Differential recognition of ORF2 protein from type 1 and type 2 porcine circoviruses and identification of immunorelevant epitopes. J Gen Virol 81:1815&#x2013;1824. 10.1099/0022-1317-81-7-1815.</Citation><ArticleIdList><ArticleId IdType="doi">10.1099/0022-1317-81-7-1815</ArticleId><ArticleId IdType="pubmed">10859388</ArticleId></ArticleIdList></Reference><Reference><Citation>Lekcharoensuk P, Morozov I, Paul PS, Thangthumniyom N, Wajjawalku W, Meng XJ. 2004. Epitope mapping of the major capsid protein of type 2 porcine circovirus (PCV2) by using chimeric PCV1 and PCV2. J Virol 78:8135&#x2013;8145. 10.1128/JVI.78.15.8135-8145.2004.</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/JVI.78.15.8135-8145.2004</ArticleId><ArticleId IdType="pmc">PMC446101</ArticleId><ArticleId IdType="pubmed">15254185</ArticleId></ArticleIdList></Reference><Reference><Citation>NCCLS. 2000. How to define and determine reference intervals in the clinical laboratory; approved guideline-second edition. NCCLS, Wayne, PA, USA.</Citation></Reference><Reference><Citation>Ilha M, Nara P, Ramamoorthy S. 2020. Early antibody responses map to non-protective, PCV2 capsid protein epitopes. Virology 540:23&#x2013;29. 10.1016/j.virol.2019.11.008.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.virol.2019.11.008</ArticleId><ArticleId IdType="pubmed">31734380</ArticleId></ArticleIdList></Reference><Reference><Citation>To KK, Cheng VC, Cai JP, Chan KH, Chen LL, Wong LH, Choi CY, Fong CH, Ng AC, Lu L, Luo CT, Situ J, Chung TW, Wong SC, Kwan GS, Sridhar S, Chan JF, Fan CY, Chuang VWM, Kok KH, Hung IF, Yuen KY. 2020. Seroprevalence of SARS-CoV-2 in Hong Kong and in residents evacuated from Hubei province, China: a multicohort study. Lancet Microbe 1:e111&#x2013;e118. 10.1016/S2666-5247(20)30053-7.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S2666-5247(20)30053-7</ArticleId><ArticleId IdType="pmc">PMC7673299</ArticleId><ArticleId IdType="pubmed">33230504</ArticleId></ArticleIdList></Reference><Reference><Citation>Martin H, Le Potier MF, Maris P. 2008. Virucidal efficacy of nine commercial disinfectants against porcine circovirus type 2. Vet J 177:388&#x2013;393. 10.1016/j.tvjl.2007.06.016.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.tvjl.2007.06.016</ArticleId><ArticleId IdType="pubmed">17851101</ArticleId></ArticleIdList></Reference><Reference><Citation>O'Dea MA, Hughes AP, Davies LJ, Muhling J, Buddle R, Wilcox GE. 2008. Thermal stability of porcine circovirus type 2 in cell culture. J Virol Methods 147:61&#x2013;66. 10.1016/j.jviromet.2007.07.029.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jviromet.2007.07.029</ArticleId><ArticleId IdType="pubmed">17889378</ArticleId></ArticleIdList></Reference><Reference><Citation>Li J, Yu T, Wang X, Zhou J, Gao R, Zhang F, Gao X, Gao S, Liu X. 2015. Comparative efficacy of experimental inactivated and live-attenuated chimeric porcine circovirus (PCV) 1-2b vaccines derived from PCV1 and PCV2b isolates originated in China. Virol J 12:113. 10.1186/s12985-015-0338-9.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s12985-015-0338-9</ArticleId><ArticleId IdType="pmc">PMC4518523</ArticleId><ArticleId IdType="pubmed">26220290</ArticleId></ArticleIdList></Reference><Reference><Citation>Karuppannan AK, Opriessnig T. 2017. Porcine circovirus type 2 (PCV2) vaccines in the context of current molecular epidemiology. Viruses 9:99. 10.3390/v9050099.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/v9050099</ArticleId><ArticleId IdType="pmc">PMC5454412</ArticleId><ArticleId IdType="pubmed">28481275</ArticleId></ArticleIdList></Reference><Reference><Citation>Ghotloo S, Golsaz-Shirazi F, Amiri MM, Jeddi-Tehrani M, Shokri F. 2020. Epitope mapping of tetanus toxin by monoclonal antibodies: implication for immunotherapy and vaccine design. Neurotox Res 37:239&#x2013;249. 10.1007/s12640-019-00096-w.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s12640-019-00096-w</ArticleId><ArticleId IdType="pubmed">31410686</ArticleId></ArticleIdList></Reference><Reference><Citation>Horiya S, MacPherson IS, Krauss IJ. 2014. Recent strategies targeting HIV glycans in vaccine design. Nat Chem Biol 10:990&#x2013;999. 10.1038/nchembio.1685.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nchembio.1685</ArticleId><ArticleId IdType="pmc">PMC4431543</ArticleId><ArticleId IdType="pubmed">25393493</ArticleId></ArticleIdList></Reference><Reference><Citation>Bricault CA, Yusim K, Seaman MS, Yoon H, Theiler J, Giorgi EE, Wagh K, Theiler M, Hraber P, Macke JP, Kreider EF, Learn GH, Hahn BH, Scheid JF, Kovacs JM, Shields JL, Lavine CL, Ghantous F, Rist M, Bayne MG, Neubauer GH, McMahan K, Peng H, Cheneau C, Jones JJ, Zeng J, Ochsenbauer C, Nkolola JP, Stephenson KE, Chen B, Gnanakaran S, Bonsignori M, Williams LD, Haynes BF, Doria-Rose N, Mascola JR, Montefiori DC, Barouch DH, Korber B. 2019. HIV-1 neutralizing antibody signatures and application to epitope-targeted vaccine design. Cell Host Microbe 25:59&#x2013;72.e8. 10.1016/j.chom.2018.12.001.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.chom.2018.12.001</ArticleId><ArticleId IdType="pmc">PMC6331341</ArticleId><ArticleId IdType="pubmed">30629920</ArticleId></ArticleIdList></Reference><Reference><Citation>Sun Z, Wang Q, Li G, Li J, Chen S, Qin T, Ma H, Peng D, Liu X. 2021. Development of an inactivated H7N9 subtype avian influenza serological DIVA vaccine using the chimeric HA epitope approach. Microbiol Spectr 9:e0068721. 10.1128/Spectrum.00687-21.</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/Spectrum.00687-21</ArticleId><ArticleId IdType="pmc">PMC8557892</ArticleId><ArticleId IdType="pubmed">34585985</ArticleId></ArticleIdList></Reference><Reference><Citation>Yu F, Song H, Wu Y, Chang SY, Wang L, Li W, Hong B, Xia S, Wang C, Khurana S, Feng Y, Wang Y, Sun Z, He B, Hou D, Manischewitz J, King LR, Song Y, Min JY, Golding H, Ji X, Lu L, Jiang S, Dimitrov DS, Ying T. 2017. A potent germline-like human monoclonal antibody targets a pH-sensitive epitope on H7N9 influenza hemagglutinin. Cell Host Microbe 22:471&#x2013;483.e5. 10.1016/j.chom.2017.08.011.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.chom.2017.08.011</ArticleId><ArticleId IdType="pmc">PMC6290738</ArticleId><ArticleId IdType="pubmed">28966056</ArticleId></ArticleIdList></Reference><Reference><Citation>Bajic G, Maron MJ, Adachi Y, Onodera T, McCarthy KR, McGee CE, Sempowski GD, Takahashi Y, Kelsoe G, Kuraoka M, Schmidt AG. 2019. Influenza antigen engineering focuses immune responses to a subdominant but broadly protective viral epitope. Cell Host Microbe 25:827&#x2013;835. 10.1016/j.chom.2019.04.003.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.chom.2019.04.003</ArticleId><ArticleId IdType="pmc">PMC6748655</ArticleId><ArticleId IdType="pubmed">31104946</ArticleId></ArticleIdList></Reference><Reference><Citation>Prue G, Baker P, Graham D, Nutting C, Greenhouse P, Lawler M. 2018. It is time for universal HPV vaccination. Lancet 392:913&#x2013;914. 10.1016/S0140-6736(18)31821-X.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0140-6736(18)31821-X</ArticleId><ArticleId IdType="pubmed">30238882</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhu FC, Meng FY, Li JX, Li XL, Mao QY, Tao H, Zhang YT, Yao X, Chu K, Chen QH, Hu YM, Wu X, Liu P, Zhu LY, Gao F, Jin H, Chen YJ, Dong YY, Liang YC, Shi NM, Ge HM, Liu L, Chen SG, Ai X, Zhang ZY, Ji YG, Luo FJ, Chen XQ, Zhang Y, Zhu LW, Liang ZL, Shen XL. 2013. Efficacy, safety, and immunology of an inactivated alum-adjuvant enterovirus 71 vaccine in children in China: a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial. Lancet 381:2024&#x2013;2032. 10.1016/S0140-6736(13)61049-1.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0140-6736(13)61049-1</ArticleId><ArticleId IdType="pubmed">23726161</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>